EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Dipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis

Tzu-Han Lin, Tung-Ying Hung, Liang-Yu Lin, Tzu-Chieh Lin, Ying-Jay Liou, Yu-Juei Hsu, Meng-Ting Wang iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70138 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Tzu-Han Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Kidney Failure, Chronic, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Evidence on the safety of antidiabetic agents in end‐stage renal disease (ESRD) patients requiring dialysis, a group often excluded from randomized controlled trials, is scant. Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), widely used for type 2 diabetes mellitus (T2DM) management in this group, have raised concerns regarding the risk of heart failure (HF). However, real‐world evidence on HF risk with DPP‐4i in dialysis‐dependent diabetic patients is limited. We aimed to assess HF safety of DPP‐4i compared with sulfonylureas (SU)/meglitinides in a nationwide T2DM population with ESRD requiring dialysis.

Methods

A new user, active comparator cohort study employing propensity score‐inverse probability of treatment weighting was conducted utilizing Taiwan's nationwide healthcare claims database (2012–2020). Evaluated outcomes included hospitalizations for HF or cardiovascular death as the primary outcome, with major adverse cardiovascular events (MACEs), all‐cause mortality, and severe hypoglycemia as secondary outcomes, using weighted Cox proportional hazards models.

Results

The study included 6882 patients initiating DPP‐4i and 6174 starting SU/meglitinides, with a mean age of 66.4 years and 53.1% male. Initiation of DPP‐4i versus SU/meglitinide was not associated with increased risks of HF hospitalizations, cardiovascular death, MACEs, or all‐cause mortality, but was significantly tied to a 44% reduced risk of severe hypoglycemia.

Conclusions

This study's findings indicate that in T2DM patients with ESRD requiring dialysis, DPP‐4i do not elevate the risk of hospitalizations for HF, cardiovascular death, or all‐cause mortality, but significantly lower the risk of severe hypoglycemia compared with SUs/meglitinides. This supports the preference for DPP‐4i over SUs or meglitinides for managing T2DM in dialysis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsKidney Failure, ChronicHeart FailureRenal DialysisHypoglycemic AgentsHumansMaleFemaleAgedMiddle AgedTaiwanSulfonylurea CompoundsHospitalizationCohort StudiesDatabases, FactualHypoglycemiaBenzamides

Stichwörter der Autor:innen

cohort studydipeptidyl peptidase‐4 inhibitorsend‐stage renal diseaseheart failuretype 2 diabetes mellitus

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSulfonylurea CompoundsHypoglycemic AgentsmeglitinideBenzamides

Autor:innen und Institutionen

  • Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, National Defense Medical Center, Taipei, Taiwan.

ORCID-Profile: Meng-Ting Wang

Zitieren

APA

Lin, T. H., Hung, T. Y., Lin, L. Y., Lin, T. C., Liou, Y. J., Hsu, Y. J., & Wang, M. T. (2025). Dipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70138

Vancouver

Lin TH, Hung TY, Lin LY, Lin TC, Liou YJ, Hsu YJ, et al. Dipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70138

BibTeX
@article{Lin2025,
  author = {Lin, Tzu-Han and Hung, Tung-Ying and Lin, Liang-Yu and Lin, Tzu-Chieh and Liou, Ying-Jay and Hsu, Yu-Juei and Wang, Meng-Ting},
  title = {Dipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70138}
}
Kostenlos starten →